Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

47.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
47.8K
Retroviruses02:33

Retroviruses

13.2K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
13.2K
Subviral Agents01:29

Subviral Agents

248
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
248
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

670
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
670
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

70
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
70
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

270
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
270

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Avoiding Pitfalls in the Assessment of Post-Void Residual Volumes in Children with Lower Urinary Tract Dysfunction.

Urology practice·2023
Same author

Association of Intrinsic Capacity with Frailty, Physical Fitness and Adverse Health Outcomes in Community-Dwelling Older Adults.

The Journal of frailty & aging·2023
Same author

Microsurgery for intracranial aneurysms: A qualitative survey on technical challenges and technological solutions.

Frontiers in surgery·2022
Same author

Efficacy of electromotive drug administration in delivering botulinum toxin a in children with neuropathic detrusor overactivity-outcomes of a pilot study.

Journal of pediatric urology·2019
Same author

Zinc Deficiency and Long-Term Outcome in Cases After Isolated Intestinal Transplantation in Taiwan.

Transplantation proceedings·2018
Same author

Cohort study of long-term survival and quality of life following pelvic exenteration.

BJS open·2018

Related Experiment Video

Updated: Oct 28, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.0K

Bulevirtide for HBV and HDV infections.

D Yardeni1, C Koh2

  • 1Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA. David.yardeni@nih.gov.

Drugs of Today (Barcelona, Spain : 1998)
|July 16, 2021
PubMed
Summary

Bulevirtide shows promise for treating Hepatitis B and D viruses by blocking viral entry into liver cells. This novel therapy offers hope for a functional cure for these severe liver infections.

Keywords:
BulevirtideHBV/HDV infectionsHepatitis BHepatitis DSodium-bile acid cotransporter inhibitorsViral entry inhibitorsViral hepatitis

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.5K
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

6.9K

Related Experiment Videos

Last Updated: Oct 28, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.0K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.5K
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

6.9K

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis B virus (HBV) and Hepatitis D virus (HDV) are major causes of liver disease, including cirrhosis and hepatocellular carcinoma (HCC).
  • Current HBV therapies suppress viral replication but do not achieve a sustained functional cure.
  • Hepatitis D virus infection, causing severe chronic hepatitis and increased HCC rates, lacks FDA-approved treatments.

Purpose of the Study:

  • To review studies supporting the EU approval of bulevirtide for chronic HDV infection.
  • To examine the efficacy of bulevirtide in treating HBV infection.

Main Methods:

  • Bulevirtide acts as a novel virion entry inhibitor.
  • It blocks the hepatocyte entry pathway by targeting the NTCP receptor.

Main Results:

  • Bulevirtide received EU authorization in July 2020 for chronic HDV in adults with compensated liver disease.
  • Studies indicate bulevirtide's potential efficacy in treating both HDV and HBV infections.

Conclusions:

  • Bulevirtide represents a promising therapeutic option for chronic HDV and HBV infections.
  • Its mechanism of blocking viral entry offers a new strategy for managing these liver diseases.